We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QSI icon
151
Quantum-Si Incorporated
QSI
$155M
$1.2M 0.08%
144,406
-15,594
-10% -$154K
AGTC
152
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.18M 0.08%
390,394
-25,490
-6% -$90.8K
ANEB
153
DELISTED
Anebulo Pharmaceuticals
ANEB
$1.16M 0.08%
172,309
-2,502
-1% -$17.5K
MRUS
154
DELISTED
Merus
MRUS
$1.12M 0.08%
50,907
-316
-0.6% -$6.78K
PTGX icon
155
CALL
Protagonist Therapeutics
PTGX
$8.79B
$1.08M 0.08%
+61,100
New +$2.6M
DCPH
156
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.01M 0.07%
+29,800
New +$951K
CRBP icon
157
Corbus Pharmaceuticals
CRBP
$166M
$968K 0.07%
31,618
-519
-2% -$20.5K
BCLI
158
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$955K 0.07%
19,303
-244
-1% -$12.8K
HARP
159
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$879K 0.06%
11,129
-231
-2% -$23.2K
TPST icon
160
Tempest Therapeutics
TPST
$13.7M
$851K 0.06%
4,523
-2,390
-35% -$465K
RGLS
161
DELISTED
Regulus Therapeutics
RGLS
$849K 0.06%
122,842
-1,757
-1% -$12.9K
HEPA
162
DELISTED
Hepion Pharmaceuticals
HEPA
$847K 0.06%
553
-812
-59% -$1.3M
ONCT
163
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$830K 0.06%
9,959
-51
-0.5% -$4.22K
TENX icon
164
Tenax Therapeutics
TENX
$363M
$826K 0.06%
+291
New +$762K
CYTO
165
DELISTED
Altamira Therapeutics Ltd
CYTO
$803K 0.06%
998
-13
-1% -$14.6K
AVIR icon
166
PUT
Atea Pharmaceuticals
AVIR
$376M
$799K 0.06%
+22,800
New +$632K
ATXS
167
DELISTED
Astria Therapeutics
ATXS
$775K 0.05%
87,580
-1,136
-1% -$10.9K
ACRS icon
168
Aclaris Therapeutics
ACRS
$726M
$770K 0.05%
42,712
-47,076
-52% -$755K
ASMB icon
169
Assembly Biosciences
ASMB
$498M
$747K 0.05%
17,905
+11,866
+196% +$497K
STTK icon
170
Shattuck Labs
STTK
$675M
$739K 0.05%
36,240
-154,090
-81% -$3.3M
BLSA
171
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$739K 0.05%
73,789
-1,311
-2% -$13.2K
PBLA
172
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
$734K 0.05%
14
– –
FLACU
173
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$725K 0.05%
73,118
-1,882
-3% -$18.9K
IMVT icon
174
Immunovant
IMVT
$7.93B
$722K 0.05%
83,046
-102,454
-55% -$924K
KNSA icon
175
Kiniksa Pharmaceuticals
KNSA
$5.8B
$677K 0.05%
+59,422
New +$774K
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.